<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The T241M polymorphism in the X-ray cross-complementing group 3 (XRCC3) had been implicated in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> susceptibility </plain></SENT>
<SENT sid="1" pm="."><plain>The previous published data on the association between XRCC3 T241M polymorphism and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk remained controversial </plain></SENT>
<SENT sid="2" pm="."><plain>Hence, we performed a meta-analysis to investigate the association between <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> susceptibility and XRCC3 T241M (61,861 cases and 84,584 controls from 157 studies) polymorphism in different <z:hpo ids='HP_0000005'>inheritance</z:hpo> models </plain></SENT>
<SENT sid="3" pm="."><plain>We used odds ratios with 95% confidence intervals to assess the strength of the association </plain></SENT>
<SENT sid="4" pm="."><plain>Overall, significantly increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk was observed in any genetic model (dominant model: odds ration [OR]=1.07, 95% confidence interval [CI]=1.00-1.13; recessive model: OR=1.15, 95% CI=1.08-1.23; additive model: OR=1.17, 95% CI=1.08-1.28) when <z:hpo ids='HP_0000001'>all</z:hpo> eligible studies were pooled into the meta-analysis </plain></SENT>
<SENT sid="5" pm="."><plain>In further stratified and sensitivity analyses, the elevated risk remained for subgroups of <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> and <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, especially in Caucasians </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, significantly decreased <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> risk was also observed </plain></SENT>
<SENT sid="7" pm="."><plain>In summary, this meta-analysis suggests the participation of XRCC3 T241M in the susceptibility for <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> and <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, especially in Caucasians, and XRCC3 T241M polymorphism is associated with decreased <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> risk </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, our work also points out the importance of new studies for T241M association in some <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types, such as <z:hpo ids='HP_0012126'>gastric cancer</z:hpo>, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and <z:hpo ids='HP_0002861'>melanoma</z:hpo> <z:e sem="disease" ids="C0007114" disease_type="Neoplastic Process" abbrv="">skin cancer</z:e>, where at least some of the covariates responsible for <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> could be controlled, to obtain a more conclusive understanding about the function of the XRCC3 polymorphism in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development </plain></SENT>
</text></document>